Aquestive Therapeutics (NASDAQ:AQST) Stock Price Down 5.9% – Here’s What Happened

Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) traded down 5.9% during trading on Monday . The stock traded as low as $5.77 and last traded at $5.6850. 1,451,721 shares were traded during trading, a decline of 26% from the average session volume of 1,970,004 shares. The stock had previously closed at $6.04.

Analyst Upgrades and Downgrades

AQST has been the subject of a number of recent analyst reports. Oppenheimer lifted their price objective on shares of Aquestive Therapeutics from $7.00 to $8.00 and gave the company an “outperform” rating in a report on Monday, September 8th. Piper Sandler lifted their price target on Aquestive Therapeutics from $5.00 to $8.00 and gave the company an “overweight” rating in a research note on Friday. Zacks Research raised Aquestive Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Friday, October 17th. Lifesci Capital upgraded Aquestive Therapeutics to a “strong-buy” rating in a research report on Wednesday, September 3rd. Finally, JMP Securities raised their price objective on Aquestive Therapeutics from $9.00 to $12.00 and gave the company a “market outperform” rating in a report on Thursday, October 9th. Two equities research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $10.00.

Aquestive Therapeutics Trading Down 7.6%

The company has a fifty day moving average of $5.88 and a 200-day moving average of $4.29. The company has a market capitalization of $680.76 million, a price-to-earnings ratio of -7.86 and a beta of 1.79.

Aquestive Therapeutics (NASDAQ:AQST) last released its earnings results on Wednesday, November 5th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.01). The firm had revenue of $12.81 million during the quarter, compared to analyst estimates of $12.94 million. Aquestive Therapeutics has set its FY 2025 guidance at EPS. As a group, equities research analysts expect that Aquestive Therapeutics, Inc. will post -0.46 EPS for the current year.

Insider Transactions at Aquestive Therapeutics

In other Aquestive Therapeutics news, insider Peter E. Boyd sold 15,000 shares of Aquestive Therapeutics stock in a transaction on Friday, September 5th. The shares were sold at an average price of $5.30, for a total transaction of $79,500.00. Following the sale, the insider owned 288,323 shares of the company’s stock, valued at $1,528,111.90. The trade was a 4.95% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Carl N. Kraus sold 20,272 shares of the company’s stock in a transaction on Wednesday, October 15th. The stock was sold at an average price of $7.00, for a total transaction of $141,904.00. Following the sale, the insider directly owned 282,475 shares of the company’s stock, valued at $1,977,325. The trade was a 6.70% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 276,770 shares of company stock worth $1,692,203. Company insiders own 7.85% of the company’s stock.

Institutional Trading of Aquestive Therapeutics

Hedge funds have recently bought and sold shares of the business. BNP Paribas Financial Markets lifted its stake in Aquestive Therapeutics by 78.3% in the 2nd quarter. BNP Paribas Financial Markets now owns 9,413 shares of the company’s stock worth $31,000 after purchasing an additional 4,134 shares in the last quarter. Summit Wealth & Retirement Planning Inc. acquired a new stake in shares of Aquestive Therapeutics in the first quarter valued at approximately $29,000. USAdvisors Wealth Management LLC purchased a new position in Aquestive Therapeutics during the second quarter worth approximately $33,000. Modern Wealth Management LLC acquired a new position in Aquestive Therapeutics during the second quarter worth $33,000. Finally, Cox Capital Mgt LLC purchased a new stake in Aquestive Therapeutics in the 3rd quarter valued at $59,000. Institutional investors and hedge funds own 32.45% of the company’s stock.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.